Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Meetings
Meetings
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
lungcanc
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
First Congress of Interventional Pulmonology & EBUS and the XI South...
lungcanc
Best of IASLC WCLC 2016
lungcanc
Highlights from IASLC WCLC 2016
lungcanc
IASLC World Conference on Lung Cancer 2016 Together Against Lung Cancer
lungcanc
Honoring Superb Advocacy at the 13th Annual Prevent Cancer Quantitative Imaging...
lungcanc
IASLC WCLC 2016: Active Prevention, Accurate Diagnosis, Advanced Care
lungcanc
2016 ASCO Annual Meeting
lungcanc
IASLC and APLCC Present 7th IASLC Asia Pacific Lung Cancer Conference
lungcanc
WCLC 2016 Together Against Lung Cancer
lungcanc
Best of the 16th World Conference on Lung Cancer in Peru
lungcanc
1
...
4
5
6
Page 5 of 6
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
